[Skip to Content]
[Skip to Content Landing]
Letters
June 26, 2002

Osteopontin as a Biomarker for Ovarian Cancer—Reply

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor

JAMA. 2002;287(24):3208-3210. doi:10.1001/jama.287.24.3206

In Reply: In response to Drs O'Regan and Fleming, our conclusion that osteopontin is up-regulated in ovarian cancer was based upon RNA expression in pure cultures of human ovarian cancer epithelial cells and pure healthy human surface epithelium. Thus, our results cannot be attributed to macrophage production. However, we agree it is possible that additional isoforms of osteopontin may have greater or lesser specificity for ovarian cancer, and should be investigated further.

First Page Preview View Large
First page PDF preview
First page PDF preview
×